基本信息
views: 0
Career Trajectory
Bio
During over 20 years in the biotechnology industry in research roles at both large pharma and small biotechnology companies, I have developed an expertise focused around the development of novel biological drug candidates, their translation into clinical use and through to commercialization.
From an early training in classic protein chemistry techniques for the expression, purification and characterization of macromolecules, early research roles in industry provided experience in the identification of new biological candidates via phage & ribosome display selection and protein engineering. Since then biotechnology industry research management roles provided experience in the cost-efficient translation of complex biologics into early-phase clinical studies; including management of the protein and bioconjugate manufacture suitable for clinical studies, pharmacology/toxicology studies, regulatory engagement and clinical protocol development. I have been involved with the development of a number of clinical agents, including small molecules, proteins/antibody fragments, full-length antibodies, dendrimers, antibody drug conjugates and radiopharmaceuticals. I have also conducted numerous GMP antibody manufacture campaigns from cell line development & banking, small-scale process development and large-scale production to GMP requirements as well as large-scale bioconjugation & fill/finish campaigns to supply clinical studies. These molecules have been at all stages of advancement: from early-clinical and Phase3 to marketing authorization submissions (serving both BLA and NDAs) but the bulk of my experience, and interest, involves the translation of preclinical candidates from the research lab into Phase1 clinical studies. In particular, my experience helps facilitate and fuel a passion for the successful advancement of novel therapies through a partnership of academia and industry: harnessing innovative discoveries from researchers but leveraging the resources and drug development knowledge of industry in order to make a difference to patients’ lives.
In my current role of Chief Scientist at Telix; a company focused on the development of targeted oncology agents and radiopharmaceuticals, a key focus is the development of new agents to enrich the pipeline. This involves the evaluation and refinement of new cancer-targeting technologies including targeting agents (antibodies, peptides and small molecules), novel bifunctional linkers and new radioisotopes to deliver novel oncology agents that deliver cytotoxic, fluorescent and radiopharmaceutical payloads for the diagnosis and treatment of cancer.
Research Interests
Papers共 6 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
B. Shuch,A. Pantuck, J.C. Bernhard, M. Morris,V. Master, A. Scott,C. Van Praet, C. Bailly,B. Onal,T. Aksoy,R. Merkx, D. Schuster,
Médecine Nucléaireno. 2 (2024): 48
S. Kleinendorst,M. Konijnenberg,G. Franssen,J. Molkenboer-Kuenen, S. Wenker,D. Boreel, D. Kroon, M. Gloudemans,K. Twumasi-Boateng,M. Wheatcroft,E. Oosterwijk,S. Heskamp
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGINGno. SUPPL 1 (2023): S157-S158
Cited0Views0Bibtex
0
0
Cited0Views0Bibtex
0
0
J. Gaschet, R. Echeynne,N. Chouin, S. Gazzola, F. Guerard,S. Gouard, S. Marionnaud-Lambot, A. Maubert, C. Alliot, P. O. Hofgaard, B. Bogen, E. Yan,
Cited0Views0Bibtex
0
0
European Urology Open Science (2020): e1482
Author Statistics
#Papers: 5
#Citation: 1
H-Index: 1
G-Index: 1
Sociability: 3
Diversity: 1
Activity: 2
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn